Assessing person-centered therapeutic innovations
White Paper
Nov 14, 2019
Are usage experience and outcome benefits from person-centered therapeutic innovations appropriately valued?

Follow-on drugs, drug plus drug combinations, drug reformulations, drug repositioning, drug plus digital applications and drug plus device combinations account for a significant proportion of medical innovations and have long been recognised as an integral part of the innovation pathway. They provide benefits for stakeholders across the healthcare system, such as patients and their caregivers, physicians and payers. They can also benefit the healthcare system through greater price competition resulting in cost savings.

DISCLAIMER: The research is sponsored by the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.